📣 Introducing Tracenable Pro: Unlock Unlimited Data Exports & Disclosures Access.

Amicus Therapeutics Inc

Common Name
Amicus Therapeutics
Country
United States
Sector
Healthcare
Industry
Biotechnology
Employees
499
Ticker
FOLD
Exchange
NASDAQ/NMS
Description
Amicus Therapeutics Inc. is a biopharmaceutical company dedicated to developing advanced therapies for rare and orphan diseases. Its primary focus is on genetic disorders, particularly lysosomal stora...

Amicus Therapeutics's GHG Emissions Data Preview

In 2023, Amicus Therapeutics completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).

However, Amicus Therapeutics has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.

Metric (tCO2e)2023202220212020 - 2017
Total Scope 1
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Total Scope 2
Unspecified Calculation Method
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Total Scope 3
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Download Data
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=FOLD&reporting_period=2024"

Verified Sources Behind Amicus Therapeutics’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Amicus Therapeutics’s data sources below and access millions more through our Disclosure Search.

a. Amicus Therapeutics's ESG Report 2024
a. Amicus Therapeutics's ESG Report 2024

Insights into Amicus Therapeutics's Operational Emissions

No operational GHG emissions data disclosed for Amicus Therapeutics in 2023.

Amicus Therapeutics's Scope 1 Emissions Over Time

202301234tCO2e
  • Total Scope 1
  • Year-over-Year Change

What are Amicus Therapeutics's Scope 1 emissions?

In 2023, the total Scope 1 emissions of Amicus Therapeutics were 0 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).a

What are Amicus Therapeutics's Scope 2 emissions?

In 2023, Amicus Therapeutics reported Scope 2 greenhouse gas (GHG) emissions of 0 tCOâ‚‚e without specifying the calculation method.a

What methodology does Amicus Therapeutics use for Scope 2 reporting?

In 2023, Amicus Therapeutics reported its Scope 2 emissions using an unspecified methodology.a

Amicus Therapeutics's Scope 2 Emissions Over Time

202301234tCO2e
  • Total Scope 2 (Unspecified Calculation Method)
Want Full Access to Amicus Therapeutics's GHG Emissions Dataset?
Sign Up